Weinstein David S, Liu Wen, Ngu Khehyong, Langevine Charles, Combs Donald W, Zhuang Shaobin, Chen Cindy, Madsen Cort S, Harper Timothy W, Robl Jeffrey A
Department of Discovery Chemistry, Bristol-Myers Squibb, Research and Development, PO Box 4000, Princeton, NJ 08543-5400, USA.
Bioorg Med Chem Lett. 2007 Sep 15;17(18):5115-20. doi: 10.1016/j.bmcl.2007.07.011. Epub 2007 Jul 13.
A series of 2,4,5-tri-substituted imidazoles has proven to be highly potent in inhibiting mammalian 15-lipoxygenase (15-LO) with excellent selectivity over human isozymes 5- and P-12-LO. Non-symmetrical sulfamides (e.g., 21a-n) were found to be suitable replacements for the earlier arylsulfonamide-containing members of this series (e.g., 2, 14a-p). Several members of these series also demonstrated potent inhibition of human 15-LO in a cell-based assay.
一系列2,4,5-三取代咪唑已被证明在抑制哺乳动物15-脂氧合酶(15-LO)方面具有高效性,并且对人同工酶5-脂氧合酶和P-12-脂氧合酶具有出色的选择性。发现非对称磺酰胺(例如21a-n)是该系列早期含芳基磺酰胺成员(例如2、14a-p)的合适替代物。这些系列中的几个成员在基于细胞的试验中也表现出对人15-LO的强效抑制作用。